Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,897 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characterization of gut microbiota profiles by disease activity in patients with Crohn's disease using data mining analysis of terminal restriction fragment length polymorphisms.
Andoh A, Kobayashi T, Kuzuoka H, Tsujikawa T, Suzuki Y, Hirai F, Matsui T, Nakamura S, Matsumoto T, Fujiyama Y. Andoh A, et al. Among authors: nakamura s. Biomed Rep. 2014 May;2(3):370-373. doi: 10.3892/br.2014.252. Epub 2014 Mar 14. Biomed Rep. 2014. PMID: 24748976 Free PMC article.
Adalimumab for the treatment of Japanese patients with intestinal Behçet's disease.
Tanida S, Inoue N, Kobayashi K, Naganuma M, Hirai F, Iizuka B, Watanabe K, Mitsuyama K, Inoue T, Ishigatsubo Y, Suzuki Y, Nagahori M, Motoya S, Nakamura S, Arora V, Robinson AM, Thakkar RB, Hibi T. Tanida S, et al. Among authors: nakamura s. Clin Gastroenterol Hepatol. 2015 May;13(5):940-8.e3. doi: 10.1016/j.cgh.2014.08.042. Epub 2014 Sep 19. Clin Gastroenterol Hepatol. 2015. PMID: 25245624 Free article. Clinical Trial.
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T. Suzuki Y, et al. Among authors: nakamura s. Inflamm Bowel Dis. 2015 Sep;21(9):2114-22. doi: 10.1097/MIB.0000000000000475. Inflamm Bowel Dis. 2015. PMID: 26218144 Clinical Trial.
Caudal type homeobox 2 expression induced by leukocytapheresis might be associated with mucosal healing in ulcerative colitis.
Tsuchiya K, Hayashi R, Fukushima K, Hibiya S, Horita N, Negi M, Itoh E, Akashi T, Eishi Y, Motoya S, Takeuchi Y, Kunisaki R, Fukunaga K, Nakamura S, Yoshimura N, Takazoe M, Iizuka B, Suzuki Y, Nagahori M, Watanabe M. Tsuchiya K, et al. Among authors: nakamura s. J Gastroenterol Hepatol. 2017 May;32(5):1032-1039. doi: 10.1111/jgh.13645. J Gastroenterol Hepatol. 2017. PMID: 27862316
Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease.
Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Watanabe K, et al. Clin Gastroenterol Hepatol. 2018 Apr;16(4):542-549.e1. doi: 10.1016/j.cgh.2017.10.036. Epub 2017 Nov 11. Clin Gastroenterol Hepatol. 2018. PMID: 29104132 Free article. Clinical Trial.
Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Kobayashi T, Hisamatsu T, Suzuki Y, Ogata H, Andoh A, Araki T, Hokari R, Iijima H, Ikeuchi H, Ishiguro Y, Kato S, Kunisaki R, Matsumoto T, Motoya S, Nagahori M, Nakamura S, Nakase H, Tsujikawa T, Sasaki M, Yokoyama K, Yoshimura N, Watanabe K, Katafuchi M, Watanabe M, Hibi T. Kobayashi T, et al. Among authors: nakamura s. Intest Res. 2018 Apr;16(2):168-177. doi: 10.5217/ir.2018.16.2.168. Epub 2018 Apr 30. Intest Res. 2018. PMID: 29743830 Free PMC article. Review.
Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab: CERISIER trial.
Hisamatsu T, Kunisaki R, Nakamura S, Tsujikawa T, Hirai F, Nakase H, Watanabe K, Yokoyama K, Nagahori M, Kanai T, Naganuma M, Michimae H, Andoh A, Yamada A, Yokoyama T, Kamata N, Tanaka S, Suzuki Y, Hibi T, Watanabe M; CERISIER Trial group. Hisamatsu T, et al. Among authors: nakamura s. Intest Res. 2018 Jul;16(3):494-498. doi: 10.5217/ir.2018.16.3.494. Epub 2018 Jul 27. Intest Res. 2018. PMID: 30090050 Free PMC article. No abstract available.
10,897 results
You have reached the last available page of results. Please see the User Guide for more information.